Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5
Lophora featured in Medwatch (in Danish) Read the article
Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5, a Promising Treatment for Depression.
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2AR therapeutics to treat psychiatric disorders, announced today that it has received approval from the European Medicines Agency (EMA) to commence a Phase I, first-in-man, randomized, placebo-controlled, single-dose escalation study for LPH-5. This study will investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of […]